Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 16

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 16
---
us assumes or gives effect to no exercise of the warrants or options described above See “Description of Share Capital” for additional information.

<div align='center'>5

RISK FACTORS</div>

You should carefully consider the risks described below and the risks described in our 2024 Annual Report which are incorporated by reference herein, as well as the financial or other information included in this prospectus or incorporated by reference in this prospectus, including our consolidated financial statements and the related notes, before you decide to buy our securities. The risks and uncertainties described below are not the only risks facing us. We may face additional risks and uncertainties not currently known to us or that we currently deem to be immaterial. Any of the risks described below, and any such additional risks, could materially adversely affect our business, financial condition or results of operations. In such case, you may lose all or part of your original investment.

The sale of a substantial amount of our ordinary shares held by the selling shareholders in the public market could adversely affect the prevailing market price of our ordinary shares.

We are registering for resale
an aggregate of 17,016,694 common shares, including 16,970,241 common shares issuable to the CLA Investor upon the conversion in full
of Initial Promissory Notes in the aggregate principal amount of $2.5 million issued or issuable under the SPAs. Sales of substantial
amounts of our common shares in the public market, or the perception that such sales might occur, could adversely affect the market price
of our common shares, and the market value of our other securities. We cannot predict if and when selling shareholders may sell such shares
in the public markets. Furthermore, in the future, we may issue additional common shares or other equity or debt securities convertible
into common shares. Any such issuance could result in substantial dilution to our existing shareholders and could cause our share price
to decline.

Our management will have immediate and broad discretion as to the use of the net proceeds from the issuance and sale of the Promissory Notes, and may not use them effectively.

We currently intend to use
the net proceeds from the issuance and sale of the Promissory Notes for general corporate purposes, which may include operating expenses,
research and development, including clinical and pre-clinical testing of our product candidates, working capital, future acquisitions
and general capital expenditures. See “Use of Proceeds.” However, our management will have broad discretion in the application
of any such net proceeds. Our shareholders